BDRX News

Interim results for the six months ended June 30, 2026

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

Borderless.xyz Deepens Africa Coverage as CrissCross Goes Live on Its Network

Result of General Meeting

Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France

Biodexa lance des activités de soutien aux patients atteints de polypose adénomateuse familiale (PAF) et aux centres de traitement en France

Result of Annual General Meeting

Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants

Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress

Postponement and Re-scheduling of Annual General Meeting